Literature DB >> 33710361

[Asymptomatic primary hyperparathyroidism : Operation or observation?]

Katja Gollisch1,2, Heide Siggelkow3,4.   

Abstract

BACKGROUND: In many cases primary hyperparathyroidism (PHPT) remains asymptomatic for years and is only detected by abnormalities in routine diagnostics. While symptomatic disease almost always requires surgical treatment, in symptom-free patients the question of whether and in what form treatment should be carried out is particularly important.
OBJECTIVE: The aim of this review is to summarize the current recommendations regarding the diagnostics and treatment of asymptomatic PHPT, taking the existing evidence into account. RESULTS AND
CONCLUSION: The diagnostics of asymptomatic PHPT is the same as for symptomatic disease. The diagnosis is made in the presence of elevated parathyroid hormone and balanced vitamin D levels when a combination of hypercalcemia, hypophosphatemia and hypercalciuria is present. Borderline laboratory findings occur especially in asymptomatic PHPT and the differential diagnosis of familial hypocalciuric hypercalcemia must be considered. Once the diagnosis is made sonography, radiography or computed tomography (CT) is used to search for nephrolithiasis or nephrocalcinosis. Regarding bone mineral density (BMD) measurements, in addition to routine measurements at the lumbar spine and femur, measurement at the distal radius is important as it is the most sensitive site for detecting osteoporosis in PHPT. An indication for parathyroidectomy is confirmed in the case of hypercalcemia > 1.0 mg/dl (>0.25 mmol/l) above the upper limit of normal, hypercalciuria > 400 mg/day (>10 mmol/day), renal insufficiency, proven osteoporosis or age < 50 years. If none of these criteria are fulfilled and surgery is not desired by the patient, annual laboratory check-ups and assessment of BMD every 1-2 years are recommended.

Entities:  

Keywords:  Bone mineral density; Familial hypocalciuric hypercalcemia; Osteoporosis; Parathyroidectomy; Vitamin D

Year:  2021        PMID: 33710361     DOI: 10.1007/s00108-021-00996-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  48 in total

1.  [Ovarian insufficiency in blepharophimosis, ptosis, epicanthus inversus].

Authors:  M Graf; W Distler; H G Schnürch; F Majewski
Journal:  Geburtshilfe Frauenheilkd       Date:  1986-03       Impact factor: 2.915

2.  The Jackson cross cylinder disproved.

Authors:  C N Sims; D G Durham
Journal:  Trans Am Ophthalmol Soc       Date:  1986

3.  Role of growth factors on human parathyroid adenoma cell proliferation.

Authors:  Giuseppe Cavallaro; Alessandra Cucina; Pierpaolo Coluccia; Luigi Petramala; Dario Cotesta; Andrea Polistena; Laura Zinnamosca; Claudio Letizia; Lodovico Rosato; Antonino Cavallaro; Giorgio De Toma
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

Review 4.  Hyperparathyroidism.

Authors:  John P Bilezikian; Leonardo Bandeira; Aliya Khan; Natalie E Cusano
Journal:  Lancet       Date:  2017-09-17       Impact factor: 79.321

Review 5.  Hyperparathyroidism.

Authors:  William D Fraser
Journal:  Lancet       Date:  2009-07-11       Impact factor: 79.321

6.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop.

Authors:  John P Bilezikian; Maria Luisa Brandi; Richard Eastell; Shonni J Silverberg; Robert Udelsman; Claudio Marcocci; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

7.  Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations.

Authors:  Natalie E Cusano; Naim M Maalouf; Patty Y Wang; Chiyuan Zhang; Serge C Cremers; Elizabeth M Haney; Douglas C Bauer; Eric S Orwoll; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2013-05-20       Impact factor: 5.958

Review 8.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

9.  Neuropsychological features in primary hyperparathyroidism: a prospective study.

Authors:  Marcella D Walker; Donald J McMahon; William B Inabnet; Ronald M Lazar; Ijeoma Brown; Susan Vardy; Felicia Cosman; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

Review 10.  Epidemiology and Diagnosis of Hypoparathyroidism.

Authors:  Bart L Clarke; Edward M Brown; Michael T Collins; Harald Jüppner; Peter Lakatos; Michael A Levine; Michael M Mannstadt; John P Bilezikian; Anatoly F Romanischen; Rajesh V Thakker
Journal:  J Clin Endocrinol Metab       Date:  2016-03-04       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.